Scientific Breakthroughs in Microvascular Calcification
Innovating Microvascular therapeutic Solutions
Scientific Breakthroughs in Microvascular Calcification
Our MISSION
Over 100 million people in the United States, 1 billion globally, suffer from accelerated vascular calcification.
There is no approved drug to cure microvascular calcification.
OUR FOCUS
Vascular calcification is an actively regulated process implying damage and death of vascular smooth muscles cells and deficiencies in calcium inhibitor proteins. We have integrated decades of vitamin K redox cycle biology with break through advancements in organic synthesis technologies to solve the world-wide increasing clinical burden of vascular calcification.
PATIENT-FOCUSED
Calciphylaxis is a devastating severe rare (<200,000 people) form of vascular calcification in which the calcium deposits block small blood vessels in skin and fat tissue. These blockages cause the development of intensely painful and debilitating chronic skin lesions without any approved treatments.
Calciphylaxis has a 1-year mortality rate of 55%.
cure
We are committed to developing therapeutics to reverse calcification and improve patient lives.
team
Founded through the initial collaboration of former senior scientists from Merck, Pfizer, Roche, Amgen, and Biogen and physicians/faculty from Harvard Medical School, Stanford University School of Medicine, Duke School of Medicine and Johns Hopkins School of Medicine.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.